1

Targeting innate, acquired and bypass resistance—with the end goal of transforming lives

ORIC was established in 2014 with a bold vision of Overcoming Resistance In Cancer.

Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time.

Our pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

1

Leadership Team

Our leadership team has advanced multiple oncology therapeutics from early-stage research to clinical trials, and ultimately to regulatory approval and commercialization at biopharmaceutical companies like Ignyta, Medivation, Aragon, Seragon, Synthorx and Genentech.

Headshot of Jacob Chacko, MD President, Chief Executive Officer and Board Member on light sage background
Jacob Chacko, MD
President, Chief Executive Officer and Board Member
Headshot of Lori Friedman, PHD Chief Scientific Officer on light sage background
Lori Friedman, PhD
Chief Scientific Officer
Headshot of Pratik Multani, MD Chief Medical Officer on light sage background
Pratik Multani, MD
Chief Medical Officer
Headshot of Matthew Panuwat Chief Business Officer on light sage background
Matthew Panuwat
Chief Business Officer
Headshot of Dominic Piscitelli Chief Financial Officer on light sage background
Dominic Piscitelli
Chief Financial Officer
Headshot of Christian V. Kuhlen, MD, JD General Counsel on light sage background
Christian V. Kuhlen, MD, JD
General Counsel
Headshot of Enda Chow Maneval, PHD Senior Vice President, Clinical Development on light sage background
Edna Chow Maneval, PhD
Senior Vice President, Clinical Development
Dan Iazzetti
Dan Iazzetti
Vice President, Head of People
1

Board of Directors

Our board has decades of experience founding and building leading oncology companies.

Richard Heyman, PhD
Chairman, Founder,
Scientific Advisory Board
Mardi C. Dier
Board Member
Chief Financial Officer of Madrigal Pharmaceuticals
Steve L. Hoerter
Board Member
President and CEO of Deciphera Pharmaceuticals
Lori Kunkel, MD
Board Member
Angie You, PhD
Board Member
CEO of Architect Therapeutics
Jacob Chacko, MD
Board Member
President and Chief Executive Officer
1

Founders

Charles Sawyers, MD
Founder,
Scientific Advisory Board
Professor, Memorial Sloan Kettering Cancer Center
Scott Lowe, PhD
Founder,
Scientific Advisory Board
Professor, Memorial Sloan Kettering Cancer Center
Richard Heyman, PhD
Chairman, Founder,
Scientific Advisory Board

Contact
Corporate Headquarters
240 E. Grand Ave
2nd Floor
South San Francisco, CA 94080
San Diego Offices
12265 El Camino Real
Suite 370
San Diego, CA 92130